Searching…
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bis...
Oct 28, 2025 · The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts.
Regeneron is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling Regeneron to identify innovative targets and compl...
Asia EMEA North America Working at Regeneron We are a team of original thinkers who work together to create life-transforming medicines for people with serious diseases. Whether it's in the laboratory or at lunch, our...
At Regeneron, our goal is to address serious medical conditions across multiple and diverse therapeutic areas. Our 14 medicines approved in the U.S. or other countries are only the beginning of our long-term commitmen...
Dive into Regeneron’s history of scientific innovation and its mission to improve the lives of patients. Learn about our decades of milestones and achievements.
Nov 8, 2025 · TARRYTOWN, N.Y., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed positive Phase 2 trial results evaluating two novel investigational factor XI an...
Aug 1, 2024 · Founded and led by physician-scientists, Regeneron 's unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in devel...
To request specific product information, report an adverse event or report a product complaint for a Regeneron product, please refer to our Medical Inquiries page.
